Needham raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $34 from $29 and keeps a Buy rating on the shares. The firm views the shares as undervalued despite the 50% increase in 2025. 2026 could be another strong year for Acadia with continued commercial execution and “de-risked upside” from the Phase 2 study data expected in mid-2026, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACAD:
- Acadia Pharmaceuticals price target raised to $37 from $32 at H.C. Wainwright
- Acadia Pharmaceuticals announces FDA approval of Daybue Stix for oral solution
- Acadia Pharmaceuticals price target raised to $25 from $24 at Stifel
- Acadia Pharmaceuticals price target raised to $29 from $24 at Mizuho
- Acadia Pharmaceuticals price target lowered to $31 from $33 at JPMorgan